Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyANNALS OF HEMATOLOGYIF2.42014-04-0425PREAI
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy (vol 75, pg 135, 1997)ANNALS OF HEMATOLOGYIF2.42013-12-181PREAI
Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cellsCANCER LETTERSIF10.11997-05-0122PRE
Impaired hemorheology in patients with postmastectomy lymphedemaBREAST CANCER RESEARCH AND TREATMENTIF31996-10-016PREAI